News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zalicus Inc. (ZLCS) Reports Financial Results For The Fourth Quarter And Year-End 2013


3/13/2014 6:53:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.

“With the successful translation of Z944 in a human clinical pain model, Zalicus has initiated a Phase 1 clinical study to evaluate the pharmacokinetics and safety of multiple modified-release formulations of Z944,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES